Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. - Wikidata - awgldk - TriplyDB

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.

http://www.wikidata.org/entity/Q35630042

about

B-cell survival factors in autoimmune rheumatic disorders Lupus nephritis: the evolving role of novel therapeutics The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications.Reduced tumour necrosis factor receptor superfamily 13C inversely correlated with tumour necrosis factor superfamily 13B in patients with immune thrombocytopenia.Lupus nephritis: lessons from murine models Role of B cells in common variable immune deficiency.Targeting B cells with biologics in systemic lupus erythematosus.BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.BAFF level increased in patients with autoimmune hemolytic anemia.Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.The expression of APRIL in Sjogren's syndrome: aberrant expression of APRIL in the salivary gland.Maintenance of the plasma cell pool is independent of memory B cells.BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency.B cell modulation in rheumatology Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus Manipulating B cell homeostasis: a key component in the advancement of targeted strategies Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma.Synovial tissues concentrate secreted APRIL.Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.B effector cells in rheumatoid arthritis and experimental arthritis.B cells and antibodies in multiple sclerosis pathogenesis and therapy.Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.The dual nature of interleukin-10 in pemphigus vulgaris.Sustained remission in lupus nephritis: still a hard road ahead.Update on the use of rituximab for intractable rheumatoid arthritis.Late-onset neutropenia after rituximab in ANCA-associated vasculitis.B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response The effects of rituximab on serum IgE and BAFF.B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia.

P2860

Q26796484-F42680B5-F60D-42F4-AE21-0242940A4209 Q26998390-E5A55C6B-61D0-4DAB-9BA9-9BBC8648EEDE Q27022645-1A9D89C8-D0D5-4018-BD14-7CB78FB76A2E Q33385389-7E54563F-772B-4972-A5FC-CC05592CB690 Q33386608-A4168443-2680-43B1-B855-2E3996C8F05A Q33415681-AC1DBBC7-9178-43DE-A109-9D626732806B Q33998360-7B6CA047-0631-40CD-9CA3-3FDC2C74A332 Q34071102-18163B07-189D-4623-B8FD-FC0B40E9E91A Q34232326-0C68F577-E8C1-4253-B4AE-1A4F104E7561 Q34245983-5D584B9F-1FE6-4A9D-A67B-5889BC6AC0F3 Q34960458-3E1237FF-F61B-487E-8B36-72CF59F587BB Q35008162-F0741E0D-C8AD-4E1C-B7A7-2693BF42B2BE Q35418255-8EF3E014-9909-42FA-A739-64D472106A96 Q35643768-ED156055-FBDD-4540-9399-D80E67B802E2 Q36106681-B397A31F-A3A2-4906-89FB-D6B3A9D1C66B Q36162832-5097D5C5-9751-43C3-805F-557064019532 Q36534521-DC6D15B0-CEF7-4AA1-9C91-8636CC020278 Q36722422-BD978232-47A5-4098-94F2-BC1306E8BC88 Q36800138-D80F4E56-A4D4-469E-AE7F-A46DB30ED679 Q36878215-6FFC9864-354B-411F-9D90-A1EE269F60B3 Q36993242-6EB3CCDE-F697-4B77-959F-89110B7B56D3 Q37177128-C6AAFBF0-56D5-46AF-B7DA-4766A41A3665 Q37350904-23A4DC6C-8B51-4787-839A-D7297C8BD7A7 Q37415143-825AA9EA-E78D-41D6-AED9-AD7705C0887E Q37454022-A2AB7C18-3CD4-4860-8F17-53AF0C0DC7E5 Q37477848-25BE693C-CC57-45CE-9D53-7E1FBD41A76D Q37517575-D2985883-BB6D-43B0-8ADA-A6CB47560842 Q37541561-A50FEC8F-F33C-41B6-8536-977DB3C1F3E3 Q37995310-D51E723B-969A-4D32-9C85-ACBE8A11C330 Q38050398-2DDCA142-D61F-4F09-B69D-B8346112D2BC Q38069890-0EC35E08-961C-41FA-9123-3A854D3B1EB9 Q38187489-94131A9C-8430-47C0-95DA-E88CDBE0CD0B Q38281273-0C3A7493-B121-4701-B40C-F500A3E9EC37 Q38641358-919AB856-7EC6-4B3B-B19B-D995DF9A523F Q38993240-F82380BD-5DBC-4013-AB4F-0B16AF9B78D5 Q39944154-7DBD12D6-A8AA-4843-8180-7215567864D1 Q41182083-37E2F1AB-AE8F-4013-8B4E-2466A01165B0 Q42574976-C95766EB-8A0A-4DE9-A154-14680DCA9448 Q42846832-83EEBE53-47FE-4D94-B633-C945341E378B Q42984862-C5D045DE-B5A1-4791-BCD7-BDCA767EE492

P2860

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.

http://www.wikidata.org/entity/Q35630042

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Differential effects on BAFF a ...... osus and rheumatoid arthritis.

@ast

Differential effects on BAFF a ...... osus and rheumatoid arthritis.

@en

type

label

Differential effects on BAFF a ...... osus and rheumatoid arthritis.

@ast

Differential effects on BAFF a ...... osus and rheumatoid arthritis.

@en

prefLabel

Differential effects on BAFF a ...... osus and rheumatoid arthritis.

@ast

Differential effects on BAFF a ...... osus and rheumatoid arthritis.

@en

P1433

Q35630042-6B509783-AC66-4222-87B1-26276E0F708D

P1476

Q35630042-C77FAFE9-7400-4F73-96FE-D2CC87FEB99C

P2093

Q35630042-2EFEFBCF-317A-4A69-A6ED-AEE0A9DFC1DE

Q35630042-303F37F2-173F-4647-BE2D-4EB78ACAE672

Q35630042-4D0872FC-39D9-4611-82EC-AB39340FFDA4

Q35630042-C9CF8767-94BE-4A48-92BB-C91ED099B039

Q35630042-E43F0AD4-2D6A-490D-BDDF-BA26E8B6EA1D

P2860

Q35630042-00029718-2385-42F8-A043-06C0C32A22EA

Q35630042-0B0C1BA0-F3AB-4810-B8F3-5885EADC8680

Q35630042-190044B8-D86E-4426-A6E1-F05AB5BB3C9B

Q35630042-1A080382-228D-4156-B520-A9C94BA5ED9F

Q35630042-21A1B933-9747-4EC1-99B9-69F75916B86B

Q35630042-287B934A-BCFF-41F8-AEB3-69AC9BDE5895

Q35630042-2880933F-5233-46F9-B953-83A8B6D0BEC9

Q35630042-48DD63DE-AD6F-4B50-B89D-C18D6B885362

Q35630042-4D9B4339-4245-4875-B256-9D42C54967FF

Q35630042-5D32C72B-2D54-42D8-ADE9-39ED504E6248

P2888

Q35630042-35CF1A5E-FA17-438D-9F76-3BD5449C6419

P304

Q35630042-F4F21D69-BAAB-474F-B5CC-DF18769577C9

P31

Q35630042-8BB9E1D9-E211-4CFD-92D7-3C472AFC2C35

P356

Q35630042-9DD10BCD-AC3D-44CB-A1C0-444855CB4C82

P433

Q35630042-91CB6698-333F-4249-9F17-CE17BE178160

P478

Q35630042-F5A0D24D-6D1A-4ACB-8473-41674A90933A

P50

Q35630042-46EEF397-0CB1-489A-AF9E-115C32AB062E

Q35630042-B50C080C-7894-40C6-9C90-02DDEE66A3F7

P577

Q35630042-196555B1-4F74-4D51-A456-875238627F7D

P5875

Q35630042-65F0F498-D04D-4C4E-BF30-ED43A0C732EB

P6179

Q35630042-7958CC33-3217-4229-A29F-645C8E55FAD0

P698

Q35630042-B6CFA950-BBFF-468C-BECF-62FBC8A65578

P932

Q35630042-98DA7749-B223-43D5-82CF-53F9C953B9B3

P356

P1433

Arthritis Research and Therapy

P1476

Differential effects on BAFF a ...... osus and rheumatoid arthritis.

@en

P2093

Christina Trollmo

http://www.w3.org/2001/XMLSchema#string

Iva Gunnarsson

http://www.w3.org/2001/XMLSchema#string

Mikael Heimbürger

http://www.w3.org/2001/XMLSchema#string

Therese Vallerskog

http://www.w3.org/2001/XMLSchema#string

Wei Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

Systemic lupus erythematosus and the type I interferon system

The role of APRIL and BAFF in lymphocyte activation

Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production

BCMA is essential for the survival of long-lived bone marrow plasma cells

The 1982 revised criteria for the classification of systemic lupus erythematosus

Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

BLyS and APRIL in rheumatoid arthritis.

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

P2888

P304

R167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR2076

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Vivianne Malmström

Marie Wahren-Herlenius

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6705607

http://www.w3.org/2001/XMLSchema#string

P6179

1051359364

http://www.w3.org/2001/XMLSchema#string

P698

17092341

http://www.w3.org/2001/XMLSchema#string

P932

1794511

http://www.w3.org/2001/XMLSchema#string